KemPharm, Inc.   Report issue

For profit Phase 3
Founded: North Liberty IA United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2017
NCT03292952
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

KemPharm, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: KemPharm, Inc. (1) Acquired (1)

arimoclomol (6 trials)

serdexmethylphenidate (AZSTARYS) (2 trials)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 2